<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>358</serviceExecutionTime><Drug id="80843"><DrugName>interferon alfa 2b follow-on biologic, Pooyesh Darou Pharmaceuticals</DrugName><DrugNamesKey><Name id="42990791">PDferon-B</Name><Name id="42758618">interferon alfa-2b</Name></DrugNamesKey><DrugSynonyms><Name><Value>interferon alfa-2b</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>PDferon-B</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>interferon alfa-2b follow-on biologic, Pooyesh Darou Pharmaceuticals</Value></Name></DrugSynonyms><CompanyOriginator id="1072500">Pooyesh Darou Pharmaceuticals</CompanyOriginator><CompaniesPrimary><Company id="1072500">Pooyesh Darou Pharmaceuticals</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1072500" type="Company"><TargetEntity id="5037836615" type="organizationId">Pooyesh Darou Biopharmaceuticals Co</TargetEntity></SourceEntity><SourceEntity id="152" type="ciIndication"><TargetEntity id="10019731" type="MEDDRA"></TargetEntity><TargetEntity id="D019694" type="MeSH"></TargetEntity><TargetEntity id="-1284790527" type="omicsDisease"></TargetEntity><TargetEntity id="429" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="153" type="ciIndication"><TargetEntity id="10019744" type="MEDDRA"></TargetEntity><TargetEntity id="D019698" type="MeSH"></TargetEntity><TargetEntity id="-776640207" type="omicsDisease"></TargetEntity><TargetEntity id="430" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1736" type="ciIndication"><TargetEntity id="C91.4" type="ICD10"></TargetEntity><TargetEntity id="10019053" type="MEDDRA"></TargetEntity><TargetEntity id="D007943" type="MeSH"></TargetEntity><TargetEntity id="58017" type="ORPHANET"></TargetEntity><TargetEntity id="-1237098648" type="omicsDisease"></TargetEntity><TargetEntity id="693" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1745" type="ciIndication"><TargetEntity id="C82" type="ICD10"></TargetEntity><TargetEntity id="D008224" type="MeSH"></TargetEntity><TargetEntity id="-1402578461" type="omicsDisease"></TargetEntity><TargetEntity id="1742" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1828" type="ciIndication"><TargetEntity id="C90.0" type="ICD10"></TargetEntity><TargetEntity id="10028228" type="MEDDRA"></TargetEntity><TargetEntity id="D009101" type="MeSH"></TargetEntity><TargetEntity id="29073" type="ORPHANET"></TargetEntity><TargetEntity id="-18870694" type="omicsDisease"></TargetEntity><TargetEntity id="710" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="205" type="ciIndication"><TargetEntity id="C43" type="ICD10"></TargetEntity><TargetEntity id="10025650" type="MEDDRA"></TargetEntity><TargetEntity id="D008545" type="MeSH"></TargetEntity><TargetEntity id="-361092282" type="omicsDisease"></TargetEntity><TargetEntity id="705" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2538" type="ciIndication"><TargetEntity id="C7A.0" type="ICD10"></TargetEntity><TargetEntity id="10007275" type="MEDDRA"></TargetEntity><TargetEntity id="D002276" type="MeSH"></TargetEntity><TargetEntity id="-670291637" type="omicsDisease"></TargetEntity><TargetEntity id="662" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="PTGT-00973" type="ciTarget"><TargetEntity id="155743165834403" type="siTarget">Interferon alpha-2</TargetEntity><TargetEntity id="-269142832" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Carcinoid tumor - Iran - Sep-2012</FirstLaunched><FirstLaunched>Follicle center lymphoma - Iran - Sep-2012</FirstLaunched><FirstLaunched>Hairy cell leukemia - Iran - Sep-2012</FirstLaunched><FirstLaunched>Hepatitis B virus infection - Iran - Sep-2012</FirstLaunched><FirstLaunched>Hepatitis C virus infection - Iran - Sep-2012</FirstLaunched><FirstLaunched>Melanoma - Iran - Sep-2012</FirstLaunched><FirstLaunched>Multiple myeloma - Iran - Sep-2012</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="152">Hepatitis B virus infection</Indication><Indication id="153">Hepatitis C virus infection</Indication><Indication id="1736">Hairy cell leukemia</Indication><Indication id="1745">Follicle center lymphoma</Indication><Indication id="1828">Multiple myeloma</Indication><Indication id="205">Melanoma</Indication><Indication id="2538">Carcinoid tumor</Indication></IndicationsPrimary><ActionsPrimary><Action id="214">Interferon alpha 2 ligand</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="2953">Anti-inflammatory</Action><Action id="991">Antiviral</Action></ActionsSecondary><Technologies><Technology id="961">Follow on biological product</Technology><Technology id="85">Protein recombinant</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="651">Intramuscular formulation</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="648">Intravenous formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra></EphmraCodes><LastModificationDate>2012-12-04T17:21:38.000Z</LastModificationDate><ChangeDateLast>2012-10-08T00:00:00.000Z</ChangeDateLast><AddedDate>2012-09-18T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="1072500"&gt;Pooyesh Darou Pharmaceuticals&lt;/ulink&gt; has developed and launched PDferon-B, a follow-on biologic version of &lt;ulink linkType="Drug" linkID="45998"&gt;interferon-alpha 2b&lt;/ulink&gt;, as an iv, im and/or sc injection, for the treatment of HBV, HCV, hairy cell leukemia, multiple myeloma, follicular lymphoma, carcinoid tumor, malignant melanoma [&lt;ulink linkType="Reference" linkID="1321962"&gt;1321962&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1324850"&gt;1324850&lt;/ulink&gt;]. The drug was presumed to be launched in Iran by September 2012 [&lt;ulink linkType="Reference" linkID="1321962"&gt;1321962&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;By September 2012, data from a study of PDferon-B in patients (n = 28) with HBeAg-negative chronic hepatitis B had been reported. 60.7% patients showed complete response and 4.6% were HBsAg seroconvert [&lt;ulink linkType="Reference" linkID="1321962"&gt;1321962&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By September 2006, a therapeutic quasi-experimental, safety and efficacy combination trial of PDferon-B with &lt;ulink linkType="Drug" linkID="5369"&gt;ribavirin&lt;/ulink&gt; had been  conducted  in patients (n = 176) with HCV infection in Iran. Treatment consisted of 48 or 24 weeks of 3 million units of sc PDferon-B administered, three times weekly, plus 1000-1200 mg oral ribavirin given twice daily depending on body mass index. The rate of end treatment virologic response (EVR), biochemical response (EBR) and sustained virologic response (SVR) for all patients were 76.1%, 83.5% and 68.2%, respectively. EVR and SVR were significantly higher in group II than group I (71.3% and 61.7% for group I patients with genotype (1a, 1b, non-typable) treated for 48 weeks, and 85.2% and 80.3% for group II with genotype 2,3 (2a,3a,3b) treated for 24 weeks, respectively; P&amp;lt;0.05) [&lt;ulink linkType="Reference" linkID="1321962"&gt;1321962&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1324850"&gt;1324850&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1072500">Pooyesh Darou Pharmaceuticals</Company><Country id="IR">Iran</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-09-10T00:00:00.000Z</StatusDate><Source id="1321962" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072500">Pooyesh Darou Pharmaceuticals</Company><Country id="IR">Iran</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-09-10T00:00:00.000Z</StatusDate><Source id="1321962" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072500">Pooyesh Darou Pharmaceuticals</Company><Country id="IR">Iran</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1736">Hairy cell leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-09-10T00:00:00.000Z</StatusDate><Source id="1321962" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072500">Pooyesh Darou Pharmaceuticals</Company><Country id="IR">Iran</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2538">Carcinoid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-09-10T00:00:00.000Z</StatusDate><Source id="1321962" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072500">Pooyesh Darou Pharmaceuticals</Company><Country id="IR">Iran</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-09-10T00:00:00.000Z</StatusDate><Source id="1321962" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072500">Pooyesh Darou Pharmaceuticals</Company><Country id="IR">Iran</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-09-10T00:00:00.000Z</StatusDate><Source id="1321962" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072500">Pooyesh Darou Pharmaceuticals</Company><Country id="IR">Iran</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="205">Melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-09-10T00:00:00.000Z</StatusDate><Source id="1321962" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1072500">Pooyesh Darou Pharmaceuticals</Company><Country id="IR">Iran</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-12-31T00:00:00.000Z</StatusDate><Source id="1324850" type="SERIAL"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00973"><Name>Interferon alpha 2 ligand</Name><SwissprotNumbers><Swissprot>P01563</Swissprot><Swissprot>P01573</Swissprot><Swissprot>P05004</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Deal Summary Added/Updated</Reason><Description>Deal summary added/updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1072500">Pooyesh Darou Pharmaceuticals</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="24669">International Center for Genetic Engineering and Biotechnology (ICGEB)</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="10">Technology - Other Proprietary</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="142776" title="Pooyesh Darou to use ICGEB's technology to manufacture recombinant DNA-based proteins"></Deal></Deals><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput>